To sum up: I expect the stock market to arrest its decline any day now, given the buildup in volume and the fact that we have retraced back to a potential support area of $130-$131 on the S&P 500 SPDR. However, that does not mean that stocks will recover to new highs.

The biotech sector finally got hit badly yesterday catching up with the rest of the market. The selling has continued this morning and it gives me an opportunity to buy some more shares of ARRY.

Investors were preparing for the biggest technology IPO on record, with due to start trading at 11 a.m. Eastern time. U.S. stock futures shake off European worries to post modest gains as investors await Facebook’s much-publicized initial public offering.

As to what’s happening with JPMorgan’s $2 billion dollar loss, no one’s told us that’s been covered and closed out. Instead as MoneyMorning.com analyst Shah Gilani who used to manage derivative risk at a bank just wrote whoever found out that JPMorgan had these huge, illiquid and opaque derivative on is now forcing JPMorgan to the wall.

The photo-pinning site just raised $100 million in a new round of financing, with Japan's Rakuten taking the leading stake. This latest round of funding values Pinterest at a healthy $1.5 billion.

The market continued its recent waterfall decline today, with the Dow getting trounced 156 points and the Nasdaq collapsing 60 points. Selling pressures are still intensifying, as a big 162 stocks hi

What About Rebalancing? Most traditional mutual funds have implemented strict short-term trading policies which discourage the sale of even a few shares of a fund which may have been purchased over the previous six months (timeframe depends on the fund). Many funds will shut investors out if they are determined to be short-term traders.

U.S. stocks held steady before the opening bell on Thursday and were flirting with an end to their recent losing streak after the Fed indicated that additional monetary easing could be on the way While the plight of Greece and the future of the euro zone will continue to weigh on investors, mounting buzz over the Facebook initial public offering along with potentially upbeat data later in the day attracted some buyers.

Big pharma is now or very soon losing lots of patents on huge profit producing drugs like cholesterol-lowering drug Lipitor and blood thinner Plavix so they foresee their sales revenues collapsing big time. In order to proactively react — remember business leaders get paid big bucks to make Big Picture decisions – being “flush with cash” they are now buying smaller biotech companies with lots of new drugs in the pipeline.